In comparison to the same period in 2024, Gilead Sciences, Inc. (GILD) reported a 2% increase in total sales to $7.1 billion in its Q2 financial results, which were released today.
As a demonstration of confidence in its diverse portfolio and possibilities for future growth, the biopharmaceutical business has increased its full-year 2025 projection for product sales and diluted earnings per share (EPS).
The company’s second-quarter diluted earnings per share (EPS) increased significantly from $1.29 in 2024 to $1.56. Higher product sales, net unrealized gains on securities, and a $190 million pre-tax in-process research and development (IPR&D) impairment charge associated with the acquisition of MYR GmbH were some of the reasons given for this.
This was a very successful second quarter for Gilead, including the FDA approval for Yeztugo as the world’s first twice-yearly HIV prevention option.
Our strong growth this quarter was driven by Biktarvy, Descovy, Trodelvy and Livdelzi, reflecting the diversity of our portfolio. As we enter the third quarter, we are increasing revenue and earnings guidance for the year, and look forward to delivering continued innovation and growth across our core therapeutic areas.
Daniel O’Day
Read More: Eli Lilly Reports Strong Q2 2025 Financial Results with 38% Revenue Growth
Strong success in the HIV business, where product sales rose 7% to $5.1 billion, was the main driver of the revenue gain. Increased demand and higher average realized prices for its HIV medications were the main drivers of this.
Additionally, the company’s treatments for chronic hepatitis B virus (HBV) and liver illness, Livdelzi and Hepcludex, witnessed a rise in demand.
decreased sales of chronic hepatitis C virus (HCV) medications and a 44% drop in Veklury (remdesivir) sales to $121 million, which reflected decreased rates of hospitalizations connected to COVID-19, somewhat offset these gains, though. Due to persistent competition, the Cell Therapy company also saw a 7% drop in product sales to $485 million.
Read More: Pfizer Reports Strong Q2 2025 Results, Raises Full-Year EPS Guidance
Gilead has increased its full-year 2025 projection in anticipation of the future. The business now projects diluted earnings per share (EPS) to be between $5.85 and $6.15 and product sales to be between $28.3 billion and $28.7 billion.
The company’s impressive performance in the first half of the year and its confidence in its capacity to sustain innovation and growth across its main therapeutic areas are reflected in the updated outlook.
Last Modified:
Graduated from the University of Kerala'20 with B.Sc. Botany & Biotechnology. Post-graduation in Biotechnology from the University of Kerala'22. Internship experience in Cancer Research.
